Answers are grounded in this paper and cite their sources.
The prognostic significance of tumor mutational burden (TMB) in melanoma remains controversial. One potential reason for the mixed results is that total TMB treats all mutations as biologically equivalent, despite evidence that different types of mutations contribute differently to a tumor's neo-antigenic profile. In particular, UV-induced and non-UV mutations may have distinct effects on tumor behavior and outcomes, but this hypothesis has been studied primarily in advanced-stage disease. We analyzed 656 stage II/III tumors from the InterMEL study to evaluate whether UV TMB and non-UV TMB are associated with melanoma-specific mortality and clinicopathologic factors. Higher UV TMB was associated with improved outcomes, while non-UV TMB was not associated with mortality. These findings suggest that an association between total TMB and outcome may be driven disproportionately by mutations associated with UV mutagenesis. Although this has previously been reported in advanced melanomas, our work demonstrates that the prognostic relevance of UV TMB extends to stage II/III tumors typically found in the clinical context. Whether this relationship reflects differences in tumor neo-antigenicity, immune recognition, or other biological properties remains to be determined.
No takes yet. Share an insight, caveat, or question.
Reynolds et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: